Hernández CF, Villarreal RJA, Soria LJA, Ambriz LR

Language: Spanish
References: 23
Page: 138-144
PDF size: 287.60 Kb.

ABSTRACT

Betamethasone treatment for fetal lung maturation has decreased perinatal morbidity and mortality but its maternal diabetogenic effect has not been well documented.
Objetive: To study the effect of betamethasone treatment for fetal lung maturation on maternal blood glucose levels in non-diabetic pregnant women.
Design: Experimental and randomized study.
Methods: 123 non-diabetic pregnant women between 26 and 34 weeks of gestation were included. They were divided in two groups: betamethasone group (women treated with betamethasone for fetal lung maturation, 12 mg IM repeated after 12 h, n=94) and control group (women who were not treated with corticosteroid, n=29). Blood glucose levels were determined at 0, 12, 24, 36 and 72 hrs. after administering betamethasone. A glucose challenge test was performed and if an abnormal value was obtained, an oral glucose tolerance test was administered. Blood glucose levels and gestational diabetes diagnosis were assessed.
Results: There was an increase in blood glucose levels after the intramuscular injection of betamethasone but the tendency was to return to base levels after three days. There was a significant difference in blood glucose levels between the groups but not in the gestational diabetes diagnosis (p=0.47, IC 95%, 2.1% [-3.05; 7.25]).
Conclusions: We concluded that the increase in maternal blood glucose levels after betamethasone therapy is significant but transitory, with a tendency to return to base levels after 72 hours.

REFERENCES

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25.

2. Sawady J, Mercer B, Wapner RJ, Zhao Y, et al. The National Institute of Child Health and Human Development. Maternal-Fetal Medicine Units Network. BEARS Study: Impact of repeated doses of antenatal corticosteroids on placental growth and histologic condition. Am J Obstet Gynecol 2007;197:(3)281e1-e8.

3. Gardner MO, Goldenberg RL. The clinical use of antenatal corticosteroids. Clin Obstet Gynecol 1995;38:746-54.

4. Canterino JC, Verma U, Visintainer PF, Elimian A, et al. Antenatal steroids and neonatal periventricular leukomalacia. Obstet Gynecol 2001;97:135-9.

5. Crowley P. Antenatal corticosteroid therapy. A meta-analysis of the randomized trials: 1972-1994. Am J Obstet Gynecol 1995;173:322-35.

6. Long CN, Katzin B, Fry EG. The adrenal cortex and carbohydrate metabolism. Endocrinology 1940;26:309-44.

7. Walfisch A, Hallak M, Mazor M. Multiple courses of antenatal steroids: Risks and benefits. Obstet Gynecol 2001;98:491-7.

8. Boggess KA, Bailit JL, Singer ME, Parisi VM, Mercer BM. Projected benefits of universal or scheduled antepartum corticosteroids to prevent neonatal morbidity: A decision analysis. Am J Obstet Gynecol 2005;193:1415-23.

9. Pratt L, Magness RR, Phemetton T, Hendricks S, et al. Repeated use of dexamethasone in rabbits: Effects of treatment variation on adrenal suppression, pulmonary maturation and pregnancy outcome. Am J Obstet Gynecol 1999;180:995-1005.

10. Holness MJ, Sugden MC. Dexamethasone during late gestation exacerbates peripheral insulin resistance and selectively targets glucose-sensitive functions in B cell and liver. Endocrinology 2001;142:3742-8.

11. Sakoda H, Ogihara T, Anai M, et al. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000;49:1700-8.

12. Pandit MK, Burke J, Gustafson AB, Minocha A, et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529-39.

13. Santos AM, Salinas AM, Villarreal PJ. Gestational diabetes: Validity of ADA and WHO diagnostic criteria using NDDG as the reference test. Diabetes Research and Clinical Practice 2006;74:322-8.

14. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;18:1039-57.

15. Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol 1997;90:880-3.

16. Haning RV, Curet LB, Poole WK, Boehnlein LM, et al. Effects of fetal sex and dexamethasone on preterm maternal serum concentrations of human chorionic gonadotropin, progesterone, estrone, estradiol and estriol. Am J Obstet Gynecol 1989;161:1549-53.

17. Qi D, Pulinilkunnil T, An D, et al. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 2004;53:1790-7.

18. Ogueh O, Johnson MR. The metabolic effect of antenatal corticosteroid therapy. Hum Reprod 2000;6:169-76.

19. Yildirim Y, Tinar S, Oner RS, Kaya B, et al. Gestational diabetes mellitus in patients receiving long-term corticosteroid therapy during pregnancy. J Perinat Med 2006;34:280-4.

20. Gurbuz A, Karateke A, Ozturk G, Kabaka C. Is 1-hour glucose screening test reliable after a short term administration of antenatal betamethasone? Am J Perinatol 2004;21:415-20.

21. Bottalico JN. Recurrent gestational diabetes: Risk factors, diagnosis, management and implications. Semin Perinatol 2007;31:176-84.

22. Branchtein L, Schmidt MI, Mengue SS, Reichelt AJ, et al. Waist circumference and waist to hip ratio are related to gestational glucose tolerance. Diabetes Care 1997;20:509-11.

23. Forsbach-Sánchez G, Tamez HE, Vázquez-Lara J. Diabetes and pregnancy. Archives of Medical Research 2005;36:291-99.